Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.
Marcel ReiserSteffen DörfelManfred HenselMark HoeslWolf-Oliver JordanMichael KoenigsmannDirk MeyerDietmar ReichertAndreas SchwarzerMoritz MarquardtKerstin KellershohnKathleen Jentsch-UllrichPublished in: European journal of haematology (2018)
Chemoimmunotherapy with rituximab is feasible and safe in a wide variety of clinical settings in CLL, including the treatment of older patients with comorbidities (ClinicalTrials.gov NCT01178086).